Nancy F. Scheraga

FDA investigator

Appears on 9 documents from 2016 to 2019, mostly at sites in New Jersey. Most often cites control of microbiological contamination (21 CFR 211.113).

9
Documents on file
4.9
Observations per 483
2016
First seen
2019
Most recent

What they cite most

From 42 observations

Activity by year

2016: 3, 2017: 2, 2018: 3, 2019: 1

Where

New Jersey 7 · New York 1 · Pennsylvania 1

Is Nancy F. Scheraga coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

9 documents, newest first
FirmOpen
483 ""ImprimisRx PharmacyApr 9, 2019 · Ledgewood, New Jersey
483 Sharp Drugs, Inc.Aug 1, 2018 · West Hampton Beach, New York
483 Amneal Complex Products Research LLCApr 18, 2018 · Bridgewater, New Jersey
483 Sun Pharmaceutical Industries, IncMar 9, 2018 · Cranbury, New Jersey
483 Diamond Drugs, Inc.Jul 21, 2017 · Indiana, Pennsylvania
483 Millers of Wyckoff, Inc.May 18, 2017 · Wyckoff, New Jersey
483 Town and Country Compounding and Consultation Services, LLCAug 22, 2016 · Ridgewood, New Jersey

About this profile

What does Nancy F. Scheraga inspect?

Nancy F. Scheraga appears on 9 documents on file covering 9 sites, mostly in New Jersey.

What do they cite most often?

21 CFR 211.113 (control of microbiological contamination), followed by 21 CFR 211.165 and 21 CFR 211.192.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Nancy F. Scheraga is dated Apr 9, 2019.

FDA Investigator Nancy F. Scheraga: 483s & Inspections · FDA Intel